Paragraph Title Here (Our Interests)
You might use this space to share more
information about your group's focus and why it
attracted your members, or to outline your
day-to-day activity. How often and where do you
meet? How do you stay current on developments
related to your interests? What plans do you have
for the future?
information about your group's focus and why it
attracted your members, or to outline your
day-to-day activity. How often and where do you
meet? How do you stay current on developments
related to your interests? What plans do you have
for the future?
Paragraph Title Here (Highlights)
Here you can tell your site visitors about your
successes as an organization. Have you contributed
to local, state, or national community events? Have
your members earned accolades or represented your
group at recent conferences? You might also
discuss notable trips, meetings, or other
developments here.
successes as an organization. Have you contributed
to local, state, or national community events? Have
your members earned accolades or represented your
group at recent conferences? You might also
discuss notable trips, meetings, or other
developments here.
8.30.04
9.05.04
9.15.04
10.02.04
10.30.04
You can use this space to
briefly describe a recent
event or group meeting.
briefly describe a recent
event or group meeting.
You can use this space to
briefly describe a recent
event or group meeting.
briefly describe a recent
event or group meeting.
You can use this space to
briefly describe a recent
event or group meeting.
briefly describe a recent
event or group meeting.
You can use this space to
briefly describe a recent
event or group meeting.
briefly describe a recent
event or group meeting.
You can use this space to
briefly describe a recent
event or group meeting.
briefly describe a recent
event or group meeting.
You can use this space to
briefly describe a recent
event or group meeting.
briefly describe a recent
event or group meeting.
The Brendan B. McGinnis Congenital CMV Foundation is a non-profit 501(c)(3) established in 2007 by Tracy McGinnis, whose son Brendan is severely disabled and developmentally delayed due to congenital CMV. The primary goals of the foundation are to raise public awareness about congenital CMV, to raise donations to support research for a vaccine for CMV, and to affect change in the medical community so that physicians will begin to test women for CMV prior to pregnancy. Ultimately, our mission is to save babies yet to be born from suffering the potentially devastating consequences of congenital CMV. Our foundation is all volunteer. No staff or board member receives any compensation. Currently on the Board of Directors for the Brendan B. McGinnis Congenital CMV Foundation |
| The Brendan B. McGinnis Congenital CMV Foundation is a non-profit 501 (c) (3) dedicated to raising public awareness about congenital CMV, to raise donations to support research for a vaccine for CMV, and to affect change in the medical community so that physicians will begin to test women for CMV prior to pregnancy. Ultimately, our mission is to save babies yet to be born from suffering the often devastating consequences of congenital CMV by eradicating this common but potentially life-altering virus. |
| Brendan B. McGinnis Congenital CMV Foundation |
| If you are considering having a baby, you need to know about congenital cytomegalovirus (CMV) infection ! |
| About Our Foundation |
© Copyright 2010. www.cmvfoundation.org Federal Tax ID #: 26-0886244
| Public Awareness and Vaccine Research Support. Working Together to Eradicate Congenital CMV Disease. Member of the External Partner Group, in conjunction with the National Center on Birth Defects and Developmental Disabilities (NCBDDD) and the Centers for Disease Control and Prevention (CDC) |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
Tracy is a CMV Mom to Brendan, age 5, who is severely disabled due to
congenital CMV. She has a Master's degree in Counseling with specializations
in both Child and Family Therapy and in School Counseling.
Tracy established the Brendan B. McGinnis Congenital CMV Foundation in
2007. It was the first non-profit foundation internationally dedicated to raising
CMV awareness, and it continues to be the only foundation dedicated to
raising both public awareness and donations for vaccine research support.
Tracy named the foundation to honor her son, Brendan. It is her heart's desire
to assure that, one day, no more babies will be born with congenital CMV.
Brendan is her inspiration and the driving force behind the foundation's work.
Tracy runs the foundation's day to day operations, including the website
design and maintenance, awareness campaign organization, product
development, parent support networking...and more.
congenital CMV. She has a Master's degree in Counseling with specializations
in both Child and Family Therapy and in School Counseling.
Tracy established the Brendan B. McGinnis Congenital CMV Foundation in
2007. It was the first non-profit foundation internationally dedicated to raising
CMV awareness, and it continues to be the only foundation dedicated to
raising both public awareness and donations for vaccine research support.
Tracy named the foundation to honor her son, Brendan. It is her heart's desire
to assure that, one day, no more babies will be born with congenital CMV.
Brendan is her inspiration and the driving force behind the foundation's work.
Tracy runs the foundation's day to day operations, including the website
design and maintenance, awareness campaign organization, product
development, parent support networking...and more.
Dr. Janet Andrews, M.D.
Director
Director
Candy is a CMV Mom to Emma, age 5, who is severely disabled due to
congenital CMV. Candy brings her experiences as a CMV Mom as well as
her professional business experience, creative ideas and talents to the
Foundation board.
congenital CMV. Candy brings her experiences as a CMV Mom as well as
her professional business experience, creative ideas and talents to the
Foundation board.
Michael McVoy, Professor, Department of Pediatrics, Virginia Commonwealth
University School of Medicine. For twenty-five years Dr. McVoy’s research has
focused almost exclusively on cytomegalovirus. In 1993 he received his Ph.D.
in Microbiology & Immunology from Virginia Commonwealth University under
the mentorship of Stuart Adler. After post-doctoral training with Edward
Mocarski at Stanford University he returned to VCU to join the faculty in the
Department of Pediatrics. His research interests include: basic mechanisms
of viral DNA replication and maturation as potential targets for antiviral
development; viral mechanisms of immune evasion and their impact on live
vaccines; and development of novel live and subunit vaccine strategies.
University School of Medicine. For twenty-five years Dr. McVoy’s research has
focused almost exclusively on cytomegalovirus. In 1993 he received his Ph.D.
in Microbiology & Immunology from Virginia Commonwealth University under
the mentorship of Stuart Adler. After post-doctoral training with Edward
Mocarski at Stanford University he returned to VCU to join the faculty in the
Department of Pediatrics. His research interests include: basic mechanisms
of viral DNA replication and maturation as potential targets for antiviral
development; viral mechanisms of immune evasion and their impact on live
vaccines; and development of novel live and subunit vaccine strategies.
Dr. Pellett's research interests are focused on understanding the biology of
human herpesviruses and improving clinical outcomes of herpesvirus
infections. He is studying two types of molecular interactions between
human cytomegalovirus and the infected cell: how the virus manipulates
cellular microRNA populations and how the virus remodels the cell to form the
factory in which new virus particles are manufactured. He is working to
identify ways to use this information to improve the diagnosis and treatment
of human cytomegalovirus infections. Dr. Pellett earned his Ph.D. from the
University of Chicago in 1986. He served as Chief of the Herpesvirus Section
at the US Centers for Disease Control and Prevention (CDC) from 1986 until
2003, and was Director of Herpesvirus Translational and Basic Research at
the Cleveland Clinic prior to joining Wayne State University in 2007.
human herpesviruses and improving clinical outcomes of herpesvirus
infections. He is studying two types of molecular interactions between
human cytomegalovirus and the infected cell: how the virus manipulates
cellular microRNA populations and how the virus remodels the cell to form the
factory in which new virus particles are manufactured. He is working to
identify ways to use this information to improve the diagnosis and treatment
of human cytomegalovirus infections. Dr. Pellett earned his Ph.D. from the
University of Chicago in 1986. He served as Chief of the Herpesvirus Section
at the US Centers for Disease Control and Prevention (CDC) from 1986 until
2003, and was Director of Herpesvirus Translational and Basic Research at
the Cleveland Clinic prior to joining Wayne State University in 2007.
Dr. Andrews, ProfessorJanet Andrews, Assistant Professor, Division of
Maternal-Fetal Medicine, Department of Obstetrics and Gynecology,
University of Iowa. Dr. Andrews’s clinical and research interests are
focused on infectious diseases and pregnancy. After receiving an M.D.
from Vanderbilt University, she completed a residency in Obstetrics and
Gynecology at University of Iowa. In 2001, Dr. Andrews began sub-specialty
training in Maternal-Fetal Medicine at the University of Iowa. In 2005, she
received a three-year scholarship from the Society for Maternal-Fetal
Medicine and AAOGF to investigate potential mechanisms of CMV infection
within the human placenta under the mentorship of Dr. Jeffery Meier at the
University of Iowa. While continuing her research endeavors, Dr. Andrews
is especially interested in promoting CMV awareness within the obstetrical
community
Maternal-Fetal Medicine, Department of Obstetrics and Gynecology,
University of Iowa. Dr. Andrews’s clinical and research interests are
focused on infectious diseases and pregnancy. After receiving an M.D.
from Vanderbilt University, she completed a residency in Obstetrics and
Gynecology at University of Iowa. In 2001, Dr. Andrews began sub-specialty
training in Maternal-Fetal Medicine at the University of Iowa. In 2005, she
received a three-year scholarship from the Society for Maternal-Fetal
Medicine and AAOGF to investigate potential mechanisms of CMV infection
within the human placenta under the mentorship of Dr. Jeffery Meier at the
University of Iowa. While continuing her research endeavors, Dr. Andrews
is especially interested in promoting CMV awareness within the obstetrical
community
Ms. Candy Wiley
Director
Director
Dr. Mark Schleiss
Director
Director
Dr. Michael McVoy
Director
Director
Mike Cannon, Ph.D.
Director
Director
Dr. Philip Pellet
Director
Director
Dr. Cannon is a research epidemiologist at the CDC’s National Center on
Birth Defects and Developmental Disabilities and an adjunct assistant
professor at Emory University’s School of Public Health. He specializes in
research on the epidemiology and prevention of congenital CMV. He has
published papers on the national prevalence of CMV infection, worldwide
prevalence of congenital CMV infection, and women’s and physician’s
knowledge and awareness of CMV. His current interests include
promoting behavioral changes to prevent CMV infection in pregnant
women and evaluating the utility of newborn CMV screening.
Birth Defects and Developmental Disabilities and an adjunct assistant
professor at Emory University’s School of Public Health. He specializes in
research on the epidemiology and prevention of congenital CMV. He has
published papers on the national prevalence of CMV infection, worldwide
prevalence of congenital CMV infection, and women’s and physician’s
knowledge and awareness of CMV. His current interests include
promoting behavioral changes to prevent CMV infection in pregnant
women and evaluating the utility of newborn CMV screening.
Tracy McGinnis
President and Founder
President and Founder
Dr. Mark Schleiss is the American Legion Endowed Professor of Pediatrics
and Director of the Division of Pediatric Infectious Diseases at the University of
Minnesota. His laboratory is broadly interested in the study of congenital
cytomegalovirus (CMV) transmission, including vaccines, antiviral drugs,
newborn screening, and viral pathogenesis. Dr. Schleiss has developed an
animal model of congenital CMV transmission, ideal for the study of CMV
vaccines designed to protect the fetus. Using this guinea-pig model, protection
against CMV transmission and disease can be engendered by vaccines
targeting viral envelope glycoproteins, as well as live, attenuated vaccines. The
recent encouraging results of a phase II study of a purified CMV glycoprotein in
a population of young women at high risk for primary CMV infection has
validated the value of the guinea-pig model, since preclinical studies of a
similar vaccine in this model demonstrated protection against CMV
transmission to the guinea-pig fetus. Dr. Schleiss is continuing to study a
variety of vaccine strategies in this model, toward the goal of defining optimal
ways of protecting newborns against the potentially devastating
consequences of congenital CMV infection.
and Director of the Division of Pediatric Infectious Diseases at the University of
Minnesota. His laboratory is broadly interested in the study of congenital
cytomegalovirus (CMV) transmission, including vaccines, antiviral drugs,
newborn screening, and viral pathogenesis. Dr. Schleiss has developed an
animal model of congenital CMV transmission, ideal for the study of CMV
vaccines designed to protect the fetus. Using this guinea-pig model, protection
against CMV transmission and disease can be engendered by vaccines
targeting viral envelope glycoproteins, as well as live, attenuated vaccines. The
recent encouraging results of a phase II study of a purified CMV glycoprotein in
a population of young women at high risk for primary CMV infection has
validated the value of the guinea-pig model, since preclinical studies of a
similar vaccine in this model demonstrated protection against CMV
transmission to the guinea-pig fetus. Dr. Schleiss is continuing to study a
variety of vaccine strategies in this model, toward the goal of defining optimal
ways of protecting newborns against the potentially devastating
consequences of congenital CMV infection.
Ms. Amy Nelson
Board Officer: Secretary
Board Officer: Secretary
Amy is a CMV Mom to Nolan, age 7, who is severely disabled due
to congenital CMV. Amy has a Bachelor's degree in business and
has been active with the deaf/blind association of Oregon.
to congenital CMV. Amy has a Bachelor's degree in business and
has been active with the deaf/blind association of Oregon.